Perimenopause
The transition years before menopause — hormones fluctuating, cycle irregular, sleep and mood shifting. Typically late 30s to mid-50s.
What changes during this transition
Estrogen and progesterone fluctuate widely during perimenopause, driving hot flashes, irregular cycles, sleep disruption, anxiety, libido changes, and progressive bone-density loss. Conventional medicine's primary lever is hormone replacement therapy (HRT) — not a peptide, but often used alongside any peptide stack. The peptides below address adjacent symptoms (sleep, libido, lean-mass preservation, mood, cognitive) without replicating HRT's hormonal action. None of them substitute for HRT in users who need it; they complement it. Bone density and cardiovascular risk shifts deserve direct medical monitoring during this window.
Important caveat
Hormonal symptoms during perimenopause warrant clinician involvement — don't substitute peptides for proper hormonal assessment (estradiol, FSH, AMH, TSH, fasting insulin). Pregnancy is still possible during perimenopause; flag pregnancy-contraindicated peptides accordingly.
Peptides editorially relevant to perimenopause
7 peptides from the library — each evidence-tiered honestly.
- PT-141 (Bremelanotide)Tier 1
Melanocortin receptor agonist
FDA-approved as Vyleesi for premenopausal HSDD. Off-label use for male erectile function and on-demand libido is widespread but supported by far thinner evidence.
- OxytocinTier 1
Posterior-pituitary neuropeptide
The labor-induction hormone (Pitocin), FDA-approved since 1962. Off-label nasal and subcutaneous use — for autism social cognition, 'bonding,' anxiolysis — has loud community framing but a messier and partly negative randomized-trial literature.
- CJC-1295Tier 3
GHRH analog
Long-acting GHRH analog often paired with a GHRP. Strong PK data in humans; outcome data is limited.
- IpamorelinTier 3
GHRP / ghrelin mimetic
Selective GH-releasing peptide with minimal cortisol or prolactin elevation in early studies. Human outcome evidence is limited.
- DSIPTier 3
Sleep-related neuropeptide (nonapeptide)
Discovered in 1977. A handful of small clinical studies in the 1980s for sleep, narcolepsy, and opioid withdrawal. The evidence is thin, old, and largely unreplicated. Tier 3.
- BPC-157Tier 3
Gastric pentadecapeptide
Extensively studied in rodents for tissue healing across tendon, gut, vascular, and CNS injury models. Human evidence is essentially absent — community framing far outpaces the data.
- KisspeptinTier 2
KISS1R agonist (hypothalamic neuropeptide)
Sits at the very top of the reproductive axis — triggers the cascade that produces sex hormones. Strong clinical-research evidence for hypogonadism and IVF use; off-label 'natural T' community use in healthy men runs ahead of the data.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.